Want to see IN:ORCHPHARMA full AI Analyst Report?

Orchid Pharma Limited (ORCHPHARMA) Price & Analysis

0 Followers

ORCHPHARMA Stock Chart & Stats

₹794.90

-₹2.05(-0.11%)

At close: Jan 08 4:00 PM EST

₹794.90

-₹2.05(-0.11%)

Day’s Range― - ―

52-Week Range₹471.30 - ₹1,096.40

Previous CloseN/A

Volume34.10K

Average Volume (3M)10.21K

Market Cap

₹53.29B

Enterprise Value₹56.14B

Total Cash (Recent Filing)₹840.74M

Total Debt (Recent Filing)₹3.63B

Price to Earnings (P/E)251.4

Beta1.29

Next Earnings

Aug 06, 2026

EPS Estimate

3.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.01

Shares Outstanding50,719,105

10 Day Avg. Volume2,303

30 Day Avg. Volume10,213

Financial Highlights & Ratios

PEG Ratio-1.50

Price to Book (P/B)1.90

Price to Sales (P/S)3.02

P/FCF Ratio-8.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)18

Revenue Forecast (FY)₹15.13B

Bulls Say, Bears Say

Bulls Say

Integrated API And Finished-dosage PlatformOrchid's integrated API and finished-dosage capabilities, plus in-house manufacturing and R&D, create durable operational flexibility. This supports regulatory filings, vertical control of supply and costs, and the ability to address both domestic and international generics demand over multiple years.

Conservative Balance Sheet And Reduced LeverageA stronger capital structure with equity materially exceeding debt and lower leverage versus earlier years enhances financial resilience. This durable strength improves capacity to fund regulatory approvals, capex, or product launches without immediate refinancing pressure.

Return To Multi-year ProfitabilityThe multi-year recovery into profitability indicates improved earnings quality and operating leverage from restructuring or higher-margin product mix. Sustained profitability over several years provides a firmer base for reinvestment and long-term commercial execution.

Bears Say

FY2026 Revenue Decline And Margin PressureThe FY2026 top-line decline and marked EBIT reduction signal structural margin and demand challenges that could persist. If product mix, pricing, or cost pressures are enduring, margins and cash generation may remain impaired for several quarters to years absent clear corrective actions.

Inconsistent And Negative Free Cash FlowRecurring negative FCF and volatile OCF reduce funding flexibility for capex, R&D, or market expansion. Large outflows despite positive OCF suggest heavy investments or working-capital strain, increasing reliance on external financing and limiting durable self-funded growth.

Volatile Revenue And Earnings GrowthSharp negative revenue and EPS growth metrics reflect execution and demand volatility. Such swings complicate planning, weaken predictability for customers and regulators, and raise the risk that recent earnings weakness could persist absent steadier commercial traction or product wins.

Orchid Pharma Limited News

Orchid Pharma Completes Dhanuka Laboratories Merger, Ups Authorised Capital

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an announcement. Orchid Pharma Limited has implemented a merger scheme...

22h ago

Orchid Pharma Finalizes Merger with Dhanuka, Boosts Authorised Capital and Sets Record Date

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) just unveiled an announcement. Orchid Pharma Limited has announced that the merger...

22h ago

Orchid Pharma says NCLT dismisses DBS Bank lease rent claim with no impact on operations

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has shared an announcement. Orchid Pharma has disclosed that the National Company...

3M ago

Orchid Pharma’s 32nd AGM: Virtual Meeting and Voting Results Announced

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an update. Orchid Pharma Limited announced the results of its...

10M ago

ORCHPHARMA FAQ

What was Orchid Pharma Limited’s price range in the past 12 months?

Orchid Pharma Limited lowest stock price was ₹471.30 and its highest was ₹1096.40 in the past 12 months.

What is Orchid Pharma Limited’s market cap?

Orchid Pharma Limited’s market cap is ₹53.29B.

When is Orchid Pharma Limited’s upcoming earnings report date?

Orchid Pharma Limited’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.

How were Orchid Pharma Limited’s earnings last quarter?

Orchid Pharma Limited released its earnings results on May 25, 2026. The company reported ₹4.7 earnings per share for the quarter, beating the consensus estimate of ₹3 by ₹1.7.

Is Orchid Pharma Limited overvalued?

According to Wall Street analysts Orchid Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orchid Pharma Limited pay dividends?

Orchid Pharma Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Orchid Pharma Limited dividends here

What is Orchid Pharma Limited’s EPS estimate?

Orchid Pharma Limited’s EPS estimate is 3.6.

How many shares outstanding does Orchid Pharma Limited have?

Orchid Pharma Limited has 50,719,105 shares outstanding.

What happened to Orchid Pharma Limited’s price movement after its last earnings report?

Orchid Pharma Limited reported an EPS of ₹4.7 in its last earnings report, beating expectations of ₹3. Following the earnings report the stock price went up 1.081%.

Which hedge fund is a major shareholder of Orchid Pharma Limited?

Currently, no hedge funds are holding shares in IN:ORCHPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orchid Pharma Limited

Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products. Its comprehensive API portfolio encompasses oral and injectable cephalosporins, various veterinary pharmaceuticals, and non-antibiotic substances. The company maintains a multi-faceted therapeutic footprint, with offerings in areas such as anti-infectives, anti-inflammatory agents, central nervous system disorders, cardiovascular health, and nutraceuticals, alongside other oral and sterile formulations. Furthermore, it provides sophisticated new drug discovery (NDD) and pharmaceutical research and development (R&D) services. Orchid Pharma also engages in global trade, distributing its products to roughly 40 nations worldwide. Additionally, it offers comprehensive liaison and support services to its clientele, covering areas like regulatory compliance, pharmacovigilance, product testing and release, sample retention, coordination with service providers, and business expansion initiatives. The entity, originally incorporated as Orchid Chemicals & Pharmaceuticals Limited, adopted its current name, Orchid Pharma Limited, in October 2015. Established in 1992, its corporate headquarters are situated in Chennai, India. The company operates as a subsidiary of Dhanuka Laboratories Limited.